<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00703547</url>
  </required_header>
  <id_info>
    <org_study_id>CRZ107432</org_study_id>
    <nct_id>NCT00703547</nct_id>
  </id_info>
  <brief_title>A First Time in Human Study of GSK586529 in Healthy Volunteers</brief_title>
  <official_title>A Single Blind, Randomized, Placebo Controlled, Crossover Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Oral Escalating Doses of GSK586529 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single blind, randomized, placebo-controlled, crossover study in twenty four healthy male
      subjects. Subjects will be divided into two cohorts with alternate panel design. The study is
      investigating the safety, tolerability and pharmacokinetics of single oral escalating doses
      of GSK586529.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2008</start_date>
  <completion_date type="Actual">April 11, 2008</completion_date>
  <primary_completion_date type="Actual">April 11, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>Pre-dose, 30 minutes, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72 and 96 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood levels of GSK586529 to determine pharmacokinetic parameters</measure>
    <time_frame>Pre-dose, 30 minutes, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72 and 96 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary recovery of GSK586529</measure>
    <time_frame>Pre-dose, 0-6, 6-12, 12-24, 24-48, 48-72 and 72-96 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Depressive Disorder and Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>Subjects receiving treatment in cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one of the following sequences; ABDF,BADF, BDAF or BDFA (A=Placebo, B= GSK586529 dose 1 (3 milligrams), D = GSK586529 dose 3, F = GSK586529 dose 5).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects receiving treatment in cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive one of the following sequences; ACEG,CAEG, CEAG or CEGA (A = Placebo, C= GSK586529 dose 2, E = GSK586529 dose 4, G = GSK586529 dose 6)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK586529 capsules</intervention_name>
    <description>GSK586529 will be provided as white gelatin capsule with a dose of 3 milligrams.</description>
    <arm_group_label>Subjects receiving treatment in cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment in cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK586529 tablets</intervention_name>
    <description>GSK586529 will be provided as a yellow film-coated tablets for oral administration at three different strengths 10 milligrams, 60 milligrams and 120 milligrams.</description>
    <arm_group_label>Subjects receiving treatment in cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment in cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets and capsules will be provided to subjects.</description>
    <arm_group_label>Subjects receiving treatment in cohort 1</arm_group_label>
    <arm_group_label>Subjects receiving treatment in cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males aged 18-45 years, inclusive.

          -  Healthy subjects, defined as individuals who are free from clinically significant
             illness or disease as determined by their (and familial) medical and psychiatric
             history, physical examination, laboratory studies, and other tests.

          -  Body weight &gt;/= 50 kg (110 lbs) and BMI within the range 18.5-29.9 kg/m2 inclusive.

          -  Demonstrates no evidence of active disease, physical or mental impairment.

          -  Self-administered Beck Depression Inventory II scale total score no greater than 9,
             and suicide question score of zero.

          -  Non-smoker (abstinence from smoking for at least 6 months before the start of the
             study).

          -  Normal electrocardiogram (subjects must have no clinically significant abnormalities
             on a 12-lead ECG and a 24 hour Holter ECG).

          -  Read, comprehend, and write English at a sufficient level to complete study-related
             materials.

        Exclusion Criteria:

          -  As a result of any of the medical interview, physical examination, evaluation of
             mental state and psychiatric history or screening investigations the physician
             responsible considers the subject unfit for the study.

          -  The subject has a positive pre-study drug/alcohol screen.

          -  A positive pre-study HIV, Hepatitis B surface antigen or positive Hepatitis C antibody

          -  The subject has a history of psychiatric illness.

          -  Any history of suicidal attempts or behavior.

          -  Abuse of alcohol defined as an average weekly intake of greater than 21 units or an
             average daily intake of greater than three units..

          -  Consumption of grapefruit juice or grapefruit within 14 days prior to the first dose
             of study medication.

          -  Any subject who is not prepared to eat the standard meals provided by the clinic or is
             a vegetarian.

          -  Any history of an endocrine disorder including, but not limited to, diabetes or
             disorders of the hypothalamus, pituitary, adrenal, or thyroid glands, or gonadal
             disorder or dysfunction of the reproductive organs.

          -  Clinically significant abnormal; total and free testosterone, LH, FSH, ACTH or
             cortisol, or TSH or T4 values at screening/baseline

          -  LFTs elevated

          -  Any other clinically significant laboratory abnormality

          -  The subject has a screening ECG with parameters outside ranges defined in the protocol
             will also be excluded.

          -  History of long QT syndrome (personal or family) or other cardiac conduction disorder,
             or other clinically significant cardiac disease.

          -  The subject has received an investigational drug or participated in any other research
             trial within 3 months or 5 half-lives, or twice the duration of the biological effect
             of any drug(whichever is longer) prior to the first dose of study medication.

          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements (including St John'sWort) within 7 days (or 14 days if the drug is a
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first
             dose of study medication, unless in the opinion of the Investigator and sponsor the
             medication will not interfere with the study procedures or compromise subject safety.

          -  History or presence of allergy to the study drug or drugs of this class, or a history
             of drug or other allergy that, in the opinion of the physician responsible,
             contraindicates their participation.

          -  Donation of more than 500 mL blood within the 3 months before dosing.

          -  An unwillingness of male subjects to abstain from sexual intercourse with pregnant or
             lactating women from the time of the first dose of study medication until 90 days
             following administration of the last dose of study medication

          -  An unwillingness of the male subject to use a condom/spermicide in addition to having
             their female partner use another form of contraception if the woman could become
             pregnant from the time of the first dose of study medication until 90 days following
             administration of the last dose of study medication.

          -  Current or recent (within one year) gastrointestinal disease; a history of
             malabsorption, esophageal reflux, peptic ulcer disease, irritable bowel syndrome;
             frequent (more than once a week) occurrence of heartburn; or any surgical intervention
             (e.g., cholecysectomy) which would be expected to influence the absorption of drugs.

          -  Average daily caffeine intake equivalent to &gt; 4 cups of coffee or &gt; 6 cups of tea.

          -  A semi-supine systolic blood pressure less than 90mmHg or greater than 140mmHg or a
             semi-supine diastolic blood pressure of less than 60mmHg or greater than 90mmHg; or a
             radial pulse rate less than 40bpm or more than 90bpm.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW10 7NS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/CRZ107432?search=study&amp;study_ids=CRZ107432#rs</url>
    <description>Results for study CRZ107432 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2008</study_first_submitted>
  <study_first_submitted_qc>June 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2008</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

